LORRAIN DANIEL S. (Chief Scientific Officer) sold 0.3% of their position (400.00 shares) of CONTINEUM THERAPEUTICS, INC. on the open market
Open‑market sale worth $6.4K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/13/2026ACC: 0001437749-26-004122
Officer· Chief Scientific Officer
Since Mar 2026
-400.00
Net shares
Net seller
$6.4K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
400.00 acquired · 800.00 disposed
Non-Derivative Transactions2
Class A Common Stock
Direct
Shares
+400.00
Price / share
$1.01
Trade value
$404.00
% of position
0.3%
2/11/2026
156.05K→156.45K
Class A Common Stock
Direct
Shares
−400.00
Price / share
$16.00
Trade value
$6.40K
% of position
0.3%
2/11/2026
156.45K→156.05K
Total
Net shares
+0.00
Net value
-$6K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock Direct | 2/11/2026 | M · Option Exercise | +400.00 | $1.01 | $404.00 | 0.3% | 156.05K | 156.45K |
| Class A Common Stock Direct | 2/11/2026 | S · Sale | −400.00 | $16.00 | $6.40K | 0.3% | 156.45K | 156.05K |
| Total | +0.00 | -$6K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Class A Common Stock
400.00 shares
Shares
−400.00
Strike price
1.01
Held after
75.53K
Exercisable
—
2/11/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Class A Common Stock400.00 shares | 2/11/2026 | M · Option Exercise | −400.00 | 1.01 | — | 75.53K |
Non-Derivative Holdings (Post-Transaction)1
Class A Common Stock
IndirectShares owned6.84K
Total
6.84K indirect6.84K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Class A Common Stock | 6.84K | Indirect |
| Total | 6.84K | 6.84K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported